Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21001855 | 0.88 | HDAC1 (0.51) | HDAC1HDAC2POLBPTGDR2KDM4E | |
| SCHEMBL22713043 | 0.81 | HDAC1 (0.46) | HDAC1HDAC2PTGDR2KDM4EALDH1A1 | |
| SCHEMBL20826130 | 0.80 | HDAC1 (0.53) | HDAC1HDAC2KDM4EALDH1A1LMNA | |
| SCHEMBL24781662 | 0.80 | HDAC1 (0.50) | HDAC1HDAC2POLBPTGDR2KDM4E | |
| SCHEMBL14148933 | 0.77 | CA12 (0.49) | HDAC1HDAC2POLBKDM4EALDH1A1 | |
| SCHEMBL1124471 | 0.75 | HDAC1 (0.54) | HDAC1HDAC2KDM4EALDH1A1LMNA | |
| SCHEMBL23156773 | 0.75 | HDAC1 (0.54) | HDAC1HDAC2POLBKDM4EALDH1A1 | |
| SCHEMBL1358017 | 0.75 | HDAC1 (0.54) | HDAC1HDAC2KDM4EALDH1A1LMNA | |
| SCHEMBL22735021 | 0.74 | HSP90AA1 (0.47) | KDM4EALDH1A1 | |
| SCHEMBL22734480 | 0.71 | PADI4 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2021-07-01 | — | — | US | disclosed |
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | SHARPIN, PIR, THPO | HDAC1 672/4885HDAC2 316/4885POLB 3663/4885 |
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | THPO, PIR, PAK6 | HDAC1 1876/4885HDAC2 1173/4885POLB 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.